- In December 2021, Roche has launched the AVENIO Edge System to simplify and automate NGS sample preparation, reducing human error and enhancing precision medicine. This fully-integrated, automated solution will strengthen Roche's sequencing technologies, improving efficiency and supporting their growth in the precision medicine market
- In November 2021, Illumina Inc., announced a partnership with Sequoia Capital China to establish first start-ups to join Genomics Incubator in China. This will increase the company’s research and development plans towards Genomics and has supported the company to establish genomics library in China
- In October 2021, ThermoFisher Scientific Inc. announced that it has launched Applied Biosystem QuantSudio Absolute Q-Digital PCR System, which is a designed to provide highly accurate results in genetic analysis. The digital PCR is already in use for monitoring cancer driven mutations in liquid biopsy. This has helped he company to increase its product portfolio
- In September 2021, ThermoFisher Scientific Inc. announced that it has entered into partnership with AstraZeneca to develop NGS-based companion diagnostics. The NGS workflow includes multiple solutions for liquid biopsy testing and solid tumor biomarkers. This is expected to expand the company’s product portfolio
- In August 2021, Illumina Inc. announced that it has acquired GRAIL to accelerate patient access to multi cancer early detection test and gene sequencing procedures. This has helped the company to increase its product portfolio
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT & SERVICES LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.2 PORTER FIVE FORCES
5 REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 ADVANCEMENTS IN LIQUID BIOPSY TECHNOLOGY
6.1.2 INCREASING INCIDENCE RATE OF CANCER
6.1.3 TECHNOLOGICAL ADVANCEMENT IN GENOMIC SEQUENCING
6.2 RESTRAINTS
6.2.1 HIGH COST OF INSTALLATION AND MAINTENANCE OF EQUIPMENT IN THE LABORATORY
6.2.2 IMPLEMENTATION OF NGS IN THE CLINICAL LAB
6.3 OPPORTUNITIES
6.3.1 INCREASING NUMBER OF PARTNERSHIPS AND COLLABORATION
6.3.2 THE INCREASING PARTICIPATION OF NEW ZEALAND IN GLOBAL ONCOLOGY CLINICAL TRIALS
6.4 CHALLENGES
6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS
6.4.2 DATA MANAGEMENT ISSUES
7 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY PRODUCTS & SERVICES
7.1 OVERVIEW
7.2 CONSUMABLES
7.2.1 KITS
7.2.2 REAGENTS
7.2.3 OTHERS
7.2.4 LIBRARY PREPARATION AND TARGET ENRICHMENT CONSUMABLES
7.2.5 SAMPLE PREPARATION CONSUMABLES
7.3 INSTRUMENTS
7.3.1 AUTOMATED
7.3.2 SEMI-AUTOMATED
7.3.3 BENCHTOP
7.3.4 STANDALONE
7.4 SERVICES
7.4.1 SEQUENCING SERVICES
7.4.2 DNA SEQUENCING
7.4.3 RNA SEQUENCING
7.4.4 DATA MANAGEMENT SERVICES
8 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY SEQUENCING TYPE
8.1 OVERVIEW
8.2 PAIRED END SEQUENCING
8.3 SINGLE READ SEQUENCING
9 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 TARGETED SEQUENCING
9.3 WHOLE EXOME SEQUENCING
9.4 WHOLE GENOME SEQUENCING
10 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 LUNG CANCER
10.3 BREAST CANCER
10.4 COLORECTAL CANCER
10.5 PROSTATE CANCER
10.6 MELANOMA
10.7 LYMPHOMA
10.8 OTHERS
11 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PUBLIC
11.2.2 PRIVATE
11.3 CLINICAL LABORATORIES
11.4 ACADEMIC & RESEARCH INSTITUTES
11.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.6 CONTRACT RESEARCH ORGANIZATIONS (CROS)
11.7 OTHERS
12 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.3.1 OFFLINE
12.3.2 ONLINE
12.4 OTHERS
13 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET
14 SWOT ANALYSIS
15 COMPANY PROFILING
15.1 ILLUMINA, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.2 THERMO FISHER SCIENTIFIC INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENTS
15.3 F. HOFFMANN-LA ROCHE LTD
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.4 QIAGEN
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 PACBIO
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENTS
15.6 AGILENT TECHNOLOGIES, INC.
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 BIO-RAD LABORATORIES, INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 CREATIVE BIOLABS
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 DEVYSER
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 MÉRIEUX NUTRISCIENCES CORPORATION
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 MACROGEN OCEANIA
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 MYRIAD GENETICS, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 SOPHIA GENETICS
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 TAKARA BIO INC.
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 ZYMO RESEARCH CORPORATION
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 PRICES OF THE ALL NGS INSTRUMENTS IN 2022
TABLE 2 PRICES OF PLATFORM/COMPANY WISE FOR NGS INSTRUMENTS IN 2022
TABLE 3 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY PRODUCTS & SERVICES, 2018-2032 (USD THOUSAND)
TABLE 4 NEW ZEALAND CONSUMABLES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 5 NEW ZEALAND CONSUMABLES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 NEW ZEALAND INSTRUMENTS IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY OPERATING MECHANISM, 2018-2032 (USD THOUSAND)
TABLE 7 NEW ZEALAND INSTRUMENTS IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 8 NEW ZEALAND SERVICES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 NEW ZEALAND SEQUENCING SERVICES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 NEW ZEALAND DATA MANAGEMENT SERVICES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY SEQUENCING TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 13 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY CANCER TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 15 NEW ZEALAND HOSPITALS IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 17 NEW ZEALAND RETAIL SALES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: SEGMENTATION
FIGURE 2 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: DATA TRIANGULATION
FIGURE 3 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: DROC ANALYSIS
FIGURE 4 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: COUNTRY MARKET ANALYSIS
FIGURE 5 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: SEGMENTATION
FIGURE 10 ADVANCEMENTS IN LIQUID BIOPSY TECHNOLOGY ARE DRIVING THE GROWTH OF THE NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET FROM 2025 TO 2032
FIGURE 11 THE TECHNOLOGY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET IN 2025 AND 2032
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET
FIGURE 13 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY PRODUCTS & SERVICES, 2024
FIGURE 14 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY PRODUCTS & SERVICES, 2025-2032 (USD THOUSAND)
FIGURE 15 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY PRODUCTS & SERVICES, CAGR (2025-2032)
FIGURE 16 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE
FIGURE 17 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY SEQUENCING TYPE, 2024
FIGURE 18 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY SEQUENCING TYPE, 2025-2032 (USD THOUSAND)
FIGURE 19 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY SEQUENCING TYPE, CAGR (2025-2032)
FIGURE 20 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY SEQUENCING TYPE, LIFELINE CURVE
FIGURE 21 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY, 2024
FIGURE 22 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY, 2025-2032 (USD THOUSAND)
FIGURE 23 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY, CAGR (2025-2032)
FIGURE 24 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 25 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY CANCER TYPE, 2024
FIGURE 26 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY CANCER TYPE, 2025-2032 (USD THOUSAND)
FIGURE 27 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY CANCER TYPE, CAGR (2025-2032)
FIGURE 28 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 29 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 30 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 31 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 32 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 33 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 34 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 35 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 36 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: COMPANY SHARE 2024 (%)
